Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Genomic signatures may soon help doctors better predict thyroid cancer risk before going to the operating room. Researchers from Henry Ford Health System found that Afirma GRID molecular signatures could distinguish benign from malignant thyroid nodules and stratify cancer aggressiveness preoperatively. The findings, presented at the American Thyroid Association Annual Meeting, could pave the way for more personalized thyroid cancer management.
Preoperative risk stratification for thyroid nodules could get a major upgrade. Researchers from Henry Ford Health System presented two retrospective analyses at the American Thyroid Association Annual Meeting showing that molecular signatures from the Afirma Genomic Resource for Intelligent Discovery (GRID) database can help distinguish benign from malignant thyroid nodules — and even characterize how aggressive a cancer might be before a patient ever enters the OR.
In the first study of 259 surgically resected thyroid nodules, malignancy was far more common in Xpression Atlas (XA)-positive nodules than XA-negative ones (88% vs. 62%). Even among XA-negative nodules, specific GRID signatures — including the epithelial-mesenchymal transition hallmark and hedgehog signaling pathway — were linked to higher odds of malignancy. In the second study of 142 patients, higher expression of a lymph node metastasis classifier was associated with intermediate-high to high-risk cancers per 2025 ATA structural risk categories.
Key Takeaways:
Why it matters: Current preoperative risk stratification doesn't yet incorporate molecular testing, but these findings suggest genomic signatures could soon enable more individualized, data-driven decisions — potentially sparing some patients from unnecessary surgery while ensuring higher-risk cases get more aggressive treatment upfront. Multicenter validation studies are the next critical step.